| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
18.26(B) |
| Last
Volume: |
1,250,341 |
Avg
Vol: |
722,222 |
| 52
Week Range: |
$143.31 - $211.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$0 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
0 |
7 |
8 |
9 |
| Total Sell Transactions |
0 |
12 |
18 |
35 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Maraganore John |
Chief Executive Officer |
• • – |
2017-11-15 |
4 |
OE |
$31.39 |
$2,322,860 |
D/D |
74,000 |
223,710 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2017-11-02 |
4 |
AS |
$130.00 |
$2,600,000 |
D/D |
(20,000) |
0 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2017-11-02 |
4 |
OE |
$30.09 |
$601,800 |
D/D |
20,000 |
20,000 |
|
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-10-30 |
4 |
AS |
$119.79 |
$4,088,967 |
D/D |
(33,666) |
11,535 |
|
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-10-30 |
4 |
OE |
$21.35 |
$718,769 |
D/D |
33,666 |
45,201 |
|
- |
|
| Soni Manmeet Singh |
Chief Financial Officer |
• – – |
2017-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
11 |
13 |
|
- |
|
| Greene Barry E |
President |
• – – |
2017-10-02 |
4 |
AS |
$125.00 |
$10,664,500 |
D/D |
(85,316) |
100,428 |
|
- |
|
| Greene Barry E |
President |
• – – |
2017-10-02 |
4 |
OE |
$21.35 |
$1,821,497 |
D/D |
85,316 |
185,744 |
|
- |
|
| Greene Barry E |
President |
• – – |
2017-09-21 |
4 |
OE |
$7.10 |
$146,042 |
D/D |
11,844 |
100,428 |
|
- |
|
| Greene Barry E |
President |
• – – |
2017-09-20 |
4 |
AS |
$100.00 |
$7,681,500 |
D/D |
(76,815) |
88,584 |
|
- |
|
| Greene Barry E |
President |
• – – |
2017-09-20 |
4 |
OE |
$31.39 |
$2,411,223 |
D/D |
76,815 |
165,399 |
|
- |
|
| Soni Manmeet Singh |
Chief Financial Officer |
• – – |
2017-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2 |
2 |
|
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-06-13 |
4 |
D |
$74.31 |
$31,953 |
D/D |
(430) |
11,535 |
|
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-06-13 |
4 |
OE |
$18.66 |
$32,007 |
D/D |
1,668 |
11,965 |
|
- |
|
| Sanofi-Aventis |
10% Owner |
– – • |
2017-05-31 |
4 |
B |
$71.87 |
$21,381,397 |
I/I |
297,501 |
10,554,134 |
1.5 |
- |
|
| Keating Laurie |
SVP, GC and Secretary |
• – – |
2017-05-30 |
4 |
B |
$65.35 |
$751,502 |
D/D |
11,500 |
11,500 |
2.74 |
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-05-23 |
4 |
AS |
$75.00 |
$825,000 |
D/D |
(11,000) |
10,297 |
|
- |
|
| Vaishnaw Akshay |
EVP, R&D |
• – – |
2017-05-23 |
4 |
OE |
$21.35 |
$234,850 |
D/D |
11,000 |
21,297 |
|
- |
|
| Mason Michael |
VP, Finance and Treasurer |
• – – |
2017-05-16 |
4 |
AS |
$70.00 |
$656,250 |
D/D |
(9,375) |
0 |
|
- |
|
| Mason Michael |
VP, Finance and Treasurer |
• – – |
2017-05-16 |
4 |
OE |
$7.10 |
$131,588 |
D/D |
9,375 |
9,375 |
|
- |
|
| Vaishnaw Akshay |
SVP, R&D |
• – – |
2017-05-15 |
4 |
AS |
$65.00 |
$2,843,750 |
D/D |
(43,750) |
10,297 |
|
- |
|
| Vaishnaw Akshay |
SVP, R&D |
• – – |
2017-05-15 |
4 |
OE |
$21.35 |
$1,262,873 |
D/D |
43,750 |
21,297 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2017-02-01 |
4 |
AS |
$39.72 |
$995,125 |
D/D |
(25,000) |
140,795 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2017-02-01 |
4 |
OE |
$31.29 |
$782,250 |
D/D |
25,000 |
165,795 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2017-01-25 |
4 |
AS |
$37.95 |
$569,250 |
D/D |
(15,000) |
140,795 |
|
- |
|
748 Records found
|
|
Page 14 of 30 |
|
|
1.60 (1.07%) 
